Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease
S. Nakao (hiroshima, Japan), Y. Kakuhiro (hiroshima, Japan), S. Sakamoto (hiroshima, Japan), Y. Horimasu (hiroshima, Japan), T. Masuda (hiroshima, Japan), S. Miyamoto (hiroshima, Japan), T. Nakashima (hiroshima, Japan), H. Iwamoto (hiroshima, Japan), S. Ohshimo (hiroshima, Japan), K. Fujitaka (hiroshima, Japan), H. Hamada (hiroshima, Japan), N. Hattori (hiroshima, Japan)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Nakao (hiroshima, Japan), Y. Kakuhiro (hiroshima, Japan), S. Sakamoto (hiroshima, Japan), Y. Horimasu (hiroshima, Japan), T. Masuda (hiroshima, Japan), S. Miyamoto (hiroshima, Japan), T. Nakashima (hiroshima, Japan), H. Iwamoto (hiroshima, Japan), S. Ohshimo (hiroshima, Japan), K. Fujitaka (hiroshima, Japan), H. Hamada (hiroshima, Japan), N. Hattori (hiroshima, Japan). Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease. 3403
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: